Breaking News, Collaborations & Alliances

Abzena Signs Cancer Research Pact with Tmunity Therapeutics

Abzena will humanize monoclonal antibodies using its Composite Human Antibody technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abzena has signed an antibody humanization agreement with Tmunity Therapeutics, a clinical stage T cell therapy company and a developer of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers.   Abzena will humanize monoclonal antibodies using its Composite Human Antibody technology. This technology combines humanization and deimmunization technologies to generate fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes.   T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters